HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $25

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Generate Biomedicines (NASDAQ:GENB) with a Buy and raises the price target from $16 to $25.